Evolution of definitions of response, progression-free survival and event-free survival in front-line studies of chronic myeloid leukemia

被引:1
|
作者
Ansstas, George [1 ]
Vij, Ravi [1 ]
机构
[1] Washington Univ, Sch Med, Sect Bone Marrow Transplant & Leukemia, St Louis, MO 63110 USA
关键词
Chronic myeloid leukemia; chronic myelogenous leukemia; progression-free survival; event-free survival; disease progression; BCR-ABL inhibitor; DIAGNOSED CHRONIC-PHASE; COMPLETE CYTOGENETIC RESPONSE; CHRONIC MYELOGENOUS LEUKEMIA; KINASE INHIBITOR THERAPY; ALPHA PLUS CYTARABINE; MOLECULAR RESPONSES; FOLLOW-UP; IMATINIB; INTERFERON; DASATINIB;
D O I
10.3109/10428194.2011.653786
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Standardized definitions of response and outcome are useful to evaluate study data, facilitate treatment guideline adherence and aid clinical decision-making. Although definitions of response in chronic myeloid leukemia (CML) have been standardized, definitions of disease progression have not been standardized, despite widespread adoption of the term to reflect development of advanced disease. This article reviews definitions of response and disease progression used for progression-free survival and event-free survival in key CML studies and implications for interpreting patient response. It is proposed that adherence to definitions of progression from the European LeukmiaNet may aid future research and therapeutic decision-making.
引用
收藏
页码:1273 / 1281
页数:9
相关论文
共 50 条
  • [1] Current Event-Free Survival After Sequential Tyrosine Kinase Inhibitor Therapy for Chronic Myeloid Leukemia
    Al-Kali, Aref
    Kantarjian, Hagop
    Shan, Jianqin
    Bassett, Roland
    Quintas-Cardama, Alfonso
    Borthakur, Gautam
    Jabbour, Elias
    Verstovsek, Srdan
    O'Brien, Susan
    Cortes, Jorge
    CANCER, 2011, 117 (02) : 327 - 335
  • [2] Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML)
    Hanfstein, B.
    Mueller, M. C.
    Hehlmann, R.
    Erben, P.
    Lauseker, M.
    Fabarius, A.
    Schnittger, S.
    Haferlach, C.
    Goehring, G.
    Proetel, U.
    Kolb, H-J
    Krause, S. W.
    Hofmann, W-K
    Schubert, J.
    Einsele, H.
    Dengler, J.
    Haenel, M.
    Falge, C.
    Kanz, L.
    Neubauer, A.
    Kneba, M.
    Stegelmann, F.
    Pfreundschuh, M.
    Waller, C. F.
    Branford, S.
    Hughes, T. P.
    Spiekermann, K.
    Baerlocher, G. M.
    Pfirrmann, M.
    Hasford, J.
    Saussele, S.
    Hochhaus, A.
    LEUKEMIA, 2012, 26 (09) : 2096 - 2102
  • [3] The Clinical Significance of Achieving Different Levels of Cytogenetic Response in Patients With Chronic Phase Chronic Myeloid Leukemia After Failure to Front-Line Therapy: Is Complete Cytogenetic Response the Only Desirable Endpoint?
    Cortes, Jorge
    Quintas-Cardama, Alfonso
    Jabbour, Elias
    O'Brien, Susan
    Verstovsek, Srdan
    Borthakur, Gautam
    Ravandi, Farhad
    Garcia-Manero, Guillermo
    Burton, Elizabeth
    Shan, Jenny
    Kantarjian, Hagop
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2011, 11 (05) : 421 - 426
  • [4] Assessing the Clinical Significance of Major (MMR) and Deep (DMR) Molecular Responses for Overall (OS), Progression-Free (PFS) and Event-Free (EFS) Survival in Patients with Chronic Myeloid Leukemia (CML) Treated with Tyrosine Kinase Inhibitors (TKIs)
    Viana, Ricardo
    Mojebi, Ali
    Aimone, Paola
    Chan, Keith
    Shirali, Rohan
    Goring, Sarah
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S295 - S296
  • [5] Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML)
    B Hanfstein
    M C Müller
    R Hehlmann
    P Erben
    M Lauseker
    A Fabarius
    S Schnittger
    C Haferlach
    G Göhring
    U Proetel
    H-J Kolb
    S W Krause
    W-K Hofmann
    J Schubert
    H Einsele
    J Dengler
    M Hänel
    C Falge
    L Kanz
    A Neubauer
    M Kneba
    F Stegelmann
    M Pfreundschuh
    C F Waller
    S Branford
    T P Hughes
    K Spiekermann
    G M Baerlocher
    M Pfirrmann
    J Hasford
    S Saußele
    A Hochhaus
    Leukemia, 2012, 26 : 2096 - 2102
  • [6] Nonadherence to Imatinib adversely affects event free survival in chronic phase chronic myeloid leukemia
    Ganesan, Prasanth
    Sagar, Tenali Gnana
    Dubashi, Biswajit
    Rajendranath, Rejiv
    Kannan, Krishnarathinam
    Cyriac, Sanju
    Nandennavar, Manjunath
    AMERICAN JOURNAL OF HEMATOLOGY, 2011, 86 (06) : 471 - 474
  • [7] Imatinib mesylate therapy of chronic phase chronic myeloid leukemia resistant or intolerant to interferon:: results and prognostic factors for response and progression-free survival in 150 patients
    Cervantes, F
    Hernández-Boluda, JC
    Steegmann, JL
    Conde, E
    Alvarez-Larrán, A
    López-Jiménez, J
    Osorio, S
    Villalón, L
    Camós, M
    García-Conde, J
    Odriozola, J
    HAEMATOLOGICA, 2003, 88 (10) : 1117 - 1122
  • [8] Initial Molecular Response at 3 Months May Predict Both Response and Event-Free Survival at 24 Months in Imatinib-Resistant or -Intolerant Patients With Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase Treated With Nilotinib
    Branford, Susan
    Kim, Dong-Wook
    Soverini, Simona
    Haque, Ariful
    Shou, Yaping
    Woodman, Richard C.
    Kantarjian, Hagop M.
    Martinelli, Giovanni
    Radich, Jerald P.
    Saglio, Giuseppe
    Hochhaus, Andreas
    Hughes, Timothy P.
    Mueller, Martin C.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (35) : 4323 - 4329
  • [9] Relationship between progression-free survival and overall survival in chronic lymphocytic leukemia: a literature-based analysis
    Beauchemin, C.
    Johnston, J. B.
    Lapierre, M. E.
    Aissa, F.
    Lachaine, J.
    CURRENT ONCOLOGY, 2015, 22 (03) : E148 - E156
  • [10] Influence of initial treatment delay on overall survival and event-free survival in childhood acute lymphoblastic leukemia
    Purnama, Irenne
    Widjajanto, Pudjo Hagung
    Damayanti, Wahyu
    PAEDIATRICA INDONESIANA, 2021, 61 (04) : 217 - 222